バクテリオファージ療法の世界市場

バクテリオファージ療法の世界市場は2030年までに15億米ドルに達する見込み

2024年に13億米ドルと推定されるバクテリオファージ療法の世界市場は、2024年から2030年にかけてCAGR 2.4%で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである大腸菌は、CAGR 1.8%を記録し、分析期間終了時には3億6,470万米ドルに達すると予測されます。黄色ブドウ球菌セグメントの成長率は、分析期間中CAGR 3.2%と推定されます。

米国市場は3億5,110万米ドルと推定、中国はCAGR4.5%で成長すると予測

米国のバクテリオファージ療法市場は、2024年に3億5,110万米ドルと推定されます。世界第2位の経済大国である中国は、2024-2030年のCAGRを4.5%として、2030年までに2億8,170万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と1.8%と予測されています。欧州では、ドイツがCAGR 1.3%で成長すると予測されています。

世界のバクテリオファージ療法市場- 主要動向と促進要因のまとめ

世界の抗菌薬耐性危機の中、バクテリオファージ療法が有望な選択肢として再浮上している理由とは？

バクテリオファージ療法- 細菌細胞に選択的に感染し、破壊するウイルスを使用-は、特に多剤耐性（MDR）感染症との闘いにおいて、従来の抗生物質に代わる有望な選択肢として再び注目を集めています。抗菌薬耐性（AMR）が世界の公衆衛生上の緊急事態へとエスカレートし、従来の抗生物質が進化する病原体に対して効きにくくなっている中、ファージ療法は、宿主マイクロバイオームへの付随的ダメージを回避し、耐性菌増殖のリスクを最小限に抑える、高度に的を絞ったアプローチを提供します。

ファージは特定の細菌株に特注できるため、緑膿菌、アシネトバクター・バウマンニ、MRSAなどの慢性感染症、バイオフィルム関連感染症、院内感染症の治療に特に有用です。広域抗生物質とは異なり、ファージ療法は有益な細菌を温存し、抗生物質と併用することで相乗効果を得ることができます。このような関心の高まりは、画期的な同情的使用事例、個別化治療に対する規制当局の開放性、化学合成薬以外の感染症治療手段の拡大が急務となっていることなどにも後押しされています。

ゲノムツール、合成生物学、規制の枠組みは、ファージ療法開発をどのように前進させているか？

ゲノミクスと合成生物学における最先端のツールは、ファージ治療薬の開発と精度に革命をもたらしています。全ゲノム配列決定により、溶菌性ファージの迅速な同定が可能になり、溶原性や毒素遺伝子のような望ましくない形質を持つ候補を排除することができます。CRISPRやその他の遺伝子編集技術は、感染力の強化、より広い宿主範囲、耐性軽減能力を持つファージの工学化に使用されています。これらのバイオエンジニアリングされたファージは、バイオフィルムを産生する病原体を標的とし、宿主の免疫反応を調節し、複雑な感染部位に治療ペイロードを送達することができます。

フレキシブルな承認パスウェイ、特に個別化治療やコンパッショネートユース治療に対する規制当局の関心は、臨床採用を加速させています。米国FDAや欧州医薬品庁（EMA）は治験薬（IND）申請を支援し、希少疾病用医薬品の指定や適応試験デザインを通じて技術革新を奨励しています。さらに、迅速な単離とGMPグレードの製造が可能なファージバンクと製造プラットフォームの確立により、スケーラブルで標準化された開発モデルが可能になり、実験的治療と広範な商業化のギャップを埋めています。

バクテリオファージ療法の需要はどこで成長し、どのアプリケーションが臨床の中心となっているか？

バクテリオファージ療法の需要は世界的に伸びており、米国、欧州（特にベルギー、ポーランド、フランス）、ロシア、そしてインドや韓国などのアジア太平洋諸国でも活発な調査が行われています。臨床試験は、嚢胞性線維症関連感染症、糖尿病性創傷治療、消化器疾患、抗生物質の失敗率が特に高い尿路感染症（UTI）などの治療分野で拡大しています。病院や学術センターは、ICU、熱傷病棟、免疫不全患者ケアにおいて、救済治療の一環としてファージ療法を試験的に導入しています。

製薬会社やバイオテクノロジー企業も、家畜への抗生物質の過剰使用が耐性菌の懸念を加速させている農業や獣医学への応用をファージ療法のターゲットとしています。これと並行して、マイクロバイオームの回復と標的腸管脱コロニー化が、ファージベースの治療薬の新たなフロンティアとして浮上しています。食品安全や衛生分野では、リステリア菌やサルモネラ菌のような病原体を制御するための天然の抗菌剤としてファージ製剤が研究されており、ファージが臨床応用されない道が開かれつつあります。

バクテリオファージ療法市場の世界的成長の原動力は？

バクテリオファージ療法市場の世界の成長の原動力となっているのは、代替抗菌薬に対する緊急の需要、精密生物学の進歩、AMRソリューションに対する官民投資の拡大です。規制当局の支持、ファージバイオテクノロジー新興企業へのベンチャーキャピタルの増加、国際的な協力関係（ファージディレクトリーや世界ファージイニシアティブなど）により、技術革新、臨床検証、そして最終的な市場拡大の枠組みが構築されつつあります。抗生物質が効かない場合にファージが有効であることを実証した有名なケーススタディは、社会的・医学的関心をさらに高めています。

狭い宿主範囲、規制の複雑さ、限られた大規模試験データなどの課題は残っているが、個別化されたファージカクテル、バイオインフォマティクス主導のマッチングアルゴリズム、GMP準拠のファージ製造エコシステムを通じて、積極的に取り組まれています。AMRが現代のヘルスケアの基盤を脅かし続ける中、極めて重要な疑問が今後の道筋を定義しています。バクテリオファージ療法は、抗生物質耐性の危機に対する次世代ソリューションとして、臨床ガイドライン、製造パイプライン、医療システムのプロトコルに組み込まれ、最後の砦の介入から最前線の精密抗菌薬へと進化することができるのか？

セグメント

標的細菌（大腸菌、黄色ブドウ球菌、レンサ球菌、緑膿菌、サルモネラ菌、その他の標的細菌）、適応疾患（尿路感染症、慢性耳炎、抜歯、慢性潰瘍性大腸炎、骨感染症、創傷・皮膚感染症、嚢胞性線維症、その他の適応疾患）、投与経路（経口剤、局所剤、非経口剤）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の41社）

• Adaptive Phage Therapeutics
• Armata Pharmaceuticals, Inc.
• BiomX Ltd.
• Biochimpharm
• ContraFect Corporation
• Eligo Bioscience
• Eliava Biopreparations Ltd.
• Enbiotix, Inc.
• Fixed-Phage Ltd.
• InnoPhage Ltd.
• Intralytix, Inc.
• iNtODEWorld, Inc.
• Locus Biosciences, Inc.
• Micreos BV
• Microgen
• Nextbiotics
• OPTIPHARM Co., Ltd.
• PhagePro, Inc.
• Phagelux, Inc.
• Pherecydes Pharma

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Bacteriophage Therapy Market to Reach US$1.5 Billion by 2030

The global market for Bacteriophage Therapy estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. E. Coli, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$364.7 Million by the end of the analysis period. Growth in the Staphylococcus Aureus segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.1 Million While China is Forecast to Grow at 4.5% CAGR

The Bacteriophage Therapy market in the U.S. is estimated at US$351.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$281.7 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Bacteriophage Therapy Market - Key Trends & Drivers Summarized

Why Is Bacteriophage Therapy Re-Emerging as a Promising Alternative Amid the Global Antimicrobial Resistance Crisis?

Bacteriophage therapy-using viruses that selectively infect and destroy bacterial cells-is gaining renewed momentum as a viable alternative to traditional antibiotics, especially in the fight against multidrug-resistant (MDR) infections. As antimicrobial resistance (AMR) escalates into a global public health emergency, with conventional antibiotics becoming less effective against evolving pathogens, phage therapy offers a highly targeted approach that bypasses the collateral damage to the host microbiome and minimizes the risk of resistance proliferation.

Phages can be custom-tailored to specific bacterial strains, making them especially valuable for treating chronic, biofilm-associated, or hospital-acquired infections such as Pseudomonas aeruginosa, Acinetobacter baumannii, and MRSA. Unlike broad-spectrum antibiotics, phage therapy preserves beneficial bacteria and can be used in combination with antibiotics for synergistic effects. The resurgence of interest is also being catalyzed by landmark compassionate use cases, regulatory openness to personalized therapies, and the growing urgency to expand the infectious disease treatment arsenal beyond chemically synthesized drugs.

How Are Genomic Tools, Synthetic Biology, and Regulatory Frameworks Advancing Phage Therapy Development?

Cutting-edge tools in genomics and synthetic biology are revolutionizing the development and precision of phage therapeutics. Whole-genome sequencing allows rapid identification of lytic phages and eliminates candidates with undesirable traits such as lysogeny or toxin genes. CRISPR and other gene editing techniques are being used to engineer phages with enhanced infectivity, broader host ranges, and resistance-mitigating capabilities. These bioengineered phages can target biofilm-producing pathogens, modulate host immune responses, and deliver therapeutic payloads in complex infection sites.

Regulatory interest in flexible approval pathways-especially for personalized and compassionate use therapies-is accelerating clinical adoption. Agencies like the U.S. FDA and European Medicines Agency (EMA) are supporting investigational new drug (IND) applications and encouraging innovation through orphan drug designations and adaptive trial designs. Additionally, the establishment of phage banks and production platforms capable of rapid isolation and GMP-grade manufacturing is enabling scalable, standardized development models-bridging the gap between experimental treatment and broader commercialization.

Where Is Demand for Bacteriophage Therapy Growing and Which Applications Are Leading Clinical Focus?

Demand for bacteriophage therapy is growing globally, with active research hubs in the United States, Europe (notably Belgium, Poland, and France), Russia, and increasingly in Asia-Pacific countries such as India and South Korea. Clinical trials are expanding across therapeutic areas such as cystic fibrosis-associated infections, diabetic wound care, gastrointestinal disorders, and urinary tract infections (UTIs), where antibiotic failure rates are particularly high. Hospitals and academic centers are piloting phage therapy in ICU settings, burn units, and immunocompromised patient care as part of salvage treatments.

Pharmaceutical and biotech firms are also targeting phage therapy for applications in agriculture and veterinary medicine, where overuse of antibiotics in livestock has accelerated resistance concerns. In parallel, microbiome restoration and targeted gut decolonization are emerging as novel frontiers for phage-based therapeutics. The food safety and sanitation sectors are exploring phage preparations as natural antibacterials to control pathogens like Listeria and Salmonella-opening non-clinical avenues for phage adoption.

What Is Fueling the Global Growth of the Bacteriophage Therapy Market?

The global growth of the bacteriophage therapy market is fueled by the urgent demand for alternative antimicrobials, advances in precision biology, and expanding public and private investment in AMR solutions. Supportive regulatory sentiment, rising venture capital in phage biotech startups, and international collaborations-such as the Phage Directory and Global Phage Initiative-are building a framework for innovation, clinical validation, and eventual market scalability. High-profile case studies demonstrating phage efficacy where antibiotics failed are further reinforcing public and medical interest.

Challenges such as narrow host range, regulatory complexity, and limited large-scale trial data remain, but are being actively addressed through personalized phage cocktails, bioinformatics-driven matching algorithms, and GMP-compliant phage manufacturing ecosystems. As AMR continues to threaten modern healthcare foundations, a pivotal question defines the path ahead: Can bacteriophage therapy evolve from last-resort intervention to front-line precision antimicrobial-integrating into clinical guidelines, manufacturing pipelines, and health system protocols as a next-generation solution to the antibiotic resistance crisis?

SCOPE OF STUDY:

The report analyzes the Bacteriophage Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Targeted Bacteria (E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella, Other Targeted Bacterias); Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications); Administration Route (Oral, Topical, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Adaptive Phage Therapeutics
• Armata Pharmaceuticals, Inc.
• BiomX Ltd.
• Biochimpharm
• ContraFect Corporation
• Eligo Bioscience
• Eliava Biopreparations Ltd.
• Enbiotix, Inc.
• Fixed-Phage Ltd.
• InnoPhage Ltd.
• Intralytix, Inc.
• iNtODEWorld, Inc.
• Locus Biosciences, Inc.
• Micreos BV
• Microgen
• Nextbiotics
• OPTIPHARM Co., Ltd.
• PhagePro, Inc.
• Phagelux, Inc.
• Pherecydes Pharma

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Bacteriophage Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Antibiotic Resistance Crisis Catalyzes Renewed Interest in Bacteriophage-Based Therapeutics
  • Precision Targeting of Pathogens Without Disrupting Microbiota Differentiates Phage Therapy
  • Expanded R&D Investments Accelerate Pipeline Development for Clinical-Grade Phage Cocktails
  • Regulatory Pathways for Personalized Phage Therapy Advance With Compassionate Use Cases
  • Partnerships Between Biotech Firms and Academia Fuel Innovation in Bacteriophage Delivery Systems
  • Interest in Chronic and Multi-Drug Resistant Infections Drives Demand for Tailored Phage Solutions
  • Advances in Synthetic Biology Enable Genetically Modified Phages With Improved Efficacy
  • Hospital Trials and Expanded Access Programs Build Clinical Credibility of Phage Therapies
  • Cold Chain Logistics and Phage Stability Remain Technical Priorities for Commercialization
  • Phage Libraries and Databases Improve Match Rates for Rapid Infection Response
  • Topical, Oral, and Intravenous Formulations Expand Application Across Infection Sites
  • Global AMR Strategies by WHO and CDC Provide Policy Backing for Phage Therapy Advancement
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Bacteriophage Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Bacteriophage Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Bacteriophage Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Bacteriophage Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for E. Coli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for E. Coli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for E. Coli by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Staphylococcus Aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Staphylococcus Aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Staphylococcus Aureus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Streptococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Streptococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Streptococcus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Pseudomonas Aeruginosa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Pseudomonas Aeruginosa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Pseudomonas Aeruginosa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Salmonella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Salmonella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Salmonella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Targeted Bacterias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Targeted Bacterias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Targeted Bacterias by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Chronic Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Chronic Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Chronic Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Bone Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Bone Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Bone Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Wound & Skin Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Wound & Skin Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Wound & Skin Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Urinary Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Chronic Otitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Chronic Otitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Chronic Otitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Dental Extraction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Dental Extraction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Dental Extraction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 65: USA Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 74: USA Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: USA 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 101: China Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: China 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Bacteriophage Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Bacteriophage Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 128: France Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: France 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 137: France Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Germany 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 149: Germany Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Germany Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Germany 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Italy 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Italy 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 161: Italy Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Italy Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Italy 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 164: UK Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: UK 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 170: UK Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: UK Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: UK 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 173: UK Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: UK Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: UK 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Spain 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 182: Spain Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Spain Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Spain 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 185: Spain Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Spain Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Spain 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Russia 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 194: Russia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Russia Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Russia 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 197: Russia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Russia Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Russia 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Europe Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Europe 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Europe Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Europe 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Bacteriophage Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Asia-Pacific Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Asia-Pacific Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Australia 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 233: Australia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Australia Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Australia 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 236: Australia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Australia Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Australia 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 239: India Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: India 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 245: India Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: India Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: India 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 248: India Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: India Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: India 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: South Korea 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 257: South Korea Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: South Korea Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: South Korea 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 260: South Korea Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: South Korea Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: South Korea 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Rest of Asia-Pacific Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Rest of Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Rest of Asia-Pacific Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Rest of Asia-Pacific 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Bacteriophage Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Bacteriophage Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Latin America 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 284: Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Latin America Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Latin America 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 287: Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Latin America Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Latin America 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Argentina 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 296: Argentina Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Argentina Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Argentina 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 299: Argentina Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Argentina Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Argentina 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Brazil 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 308: Brazil Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Brazil Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Brazil 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 311: Brazil Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Brazil Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Brazil 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Mexico 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 320: Mexico Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Mexico Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Mexico 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 323: Mexico Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Mexico Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Mexico 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Latin America Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Rest of Latin America 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Rest of Latin America Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Rest of Latin America 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Bacteriophage Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Bacteriophage Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Middle East 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 347: Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Middle East Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Middle East 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 350: Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Middle East Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Middle East 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Iran 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 359: Iran Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Iran Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Iran 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 362: Iran Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Iran Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Iran 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Israel 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 371: Israel Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Israel Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Israel 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 374: Israel Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Israel Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Israel 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Saudi Arabia Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Saudi Arabia 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Saudi Arabia Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Saudi Arabia 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: UAE 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 395: UAE Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: UAE Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: UAE 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 398: UAE Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: UAE Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: UAE 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Middle East Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Rest of Middle East 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Rest of Middle East Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 412: Rest of Middle East 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Bacteriophage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Bacteriophage Therapy by Targeted Bacteria - E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Bacteriophage Therapy by Targeted Bacteria - Percentage Breakdown of Value Sales for E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacterias for the Years 2015, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Bacteriophage Therapy by Disease Indication - Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 418: Africa 15-Year Perspective for Bacteriophage Therapy by Disease Indication - Percentage Breakdown of Value Sales for Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications, Urinary Tract Infections, Chronic Otitis and Dental Extraction for the Years 2015, 2025 & 2030
  • TABLE 419: Africa Recent Past, Current & Future Analysis for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Africa Historic Review for Bacteriophage Therapy by Administration Route - Oral, Topical and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 421: Africa 15-Year Perspective for Bacteriophage Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Parenteral for the Years 2015, 2025 & 2030
  • TABLE 422: Africa Recent Past, Current & Future Analysis for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Africa Historic Review for Bacteriophage Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 424: Africa 15-Year Perspective for Bacteriophage Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION